Texas Permanent School Fund Corp Raises Stock Holdings in Pediatrix Medical Group, Inc. (NYSE:MD)

Texas Permanent School Fund Corp raised its position in Pediatrix Medical Group, Inc. (NYSE:MD) by 29.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 93,367 shares of the company’s stock after buying an additional 21,351 shares during the quarter. Texas Permanent School Fund Corp owned approximately 0.11% of Pediatrix Medical Group worth $705,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in Pediatrix Medical Group in the second quarter valued at approximately $31,000. Innealta Capital LLC purchased a new stake in Pediatrix Medical Group in the second quarter valued at approximately $33,000. Nisa Investment Advisors LLC lifted its stake in Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after buying an additional 1,524 shares during the last quarter. Virtu Financial LLC purchased a new stake in Pediatrix Medical Group in the first quarter valued at approximately $124,000. Finally, Ballentine Partners LLC purchased a new stake in Pediatrix Medical Group in the second quarter valued at approximately $132,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Insider Activity

In other news, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares in the company, valued at $343,783.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares in the company, valued at $343,783.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO C Marc Richards sold 17,438 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $10.08, for a total value of $175,775.04. Following the completion of the sale, the chief financial officer now owns 175,347 shares in the company, valued at $1,767,497.76. The disclosure for this sale can be found here. Insiders have sold 68,100 shares of company stock worth $701,889 over the last three months. 2.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MD. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. UBS Group upped their price target on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price target for the company in a research note on Friday, June 7th. Finally, Truist Financial upped their price target on Pediatrix Medical Group from $8.00 to $10.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Six investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, Pediatrix Medical Group presently has a consensus rating of “Hold” and an average target price of $9.30.

Pediatrix Medical Group Stock Down 2.9 %

Pediatrix Medical Group stock opened at $10.56 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38. The firm has a market capitalization of $888.59 million, a price-to-earnings ratio of -12.42, a price-to-earnings-growth ratio of 1.68 and a beta of 1.56. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $13.01. The stock’s fifty day moving average is $9.71 and its two-hundred day moving average is $8.82.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.03. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The company had revenue of $504.30 million for the quarter, compared to analyst estimates of $505.49 million. During the same quarter in the prior year, the company earned $0.37 earnings per share. Pediatrix Medical Group’s revenue was up .7% compared to the same quarter last year. Analysts predict that Pediatrix Medical Group, Inc. will post 1.18 EPS for the current fiscal year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.